The next forum for unraveling FDA off-label marketing rules: State and federal legislatures

Michael S Sinha and Aaron S Kesselheim

PLOS Medicine, 2018, vol. 15, issue 5, 1-3

Abstract: In a Guest Editorial, Aaron S. Kesselheim and Michael S. Sinha show how federal and state legislation to allow promotion of drugs for non-approved uses threatens to undermine the FDA's public health mission.

Date: 2018
References: View complete reference list from CitEc
Citations:

Downloads: (external link)
https://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1002564 (text/html)
https://journals.plos.org/plosmedicine/article/fil ... 02564&type=printable (application/pdf)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:plo:pmed00:1002564

DOI: 10.1371/journal.pmed.1002564

Access Statistics for this article

More articles in PLOS Medicine from Public Library of Science
Bibliographic data for series maintained by plosmedicine ().